Optimal Treatments for NSCLC Patients Harboring Primary or Acquired Amplification
Background : In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However, the relative efficacy of different therapeutics in primary NSCLC patients with MET amplification and the treatment options...
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
SAGE Publishing
2022-09-01
|
| 丛编: | Technology in Cancer Research & Treatment |
| 在线阅读: | https://doi.org/10.1177/15330338221128414 |